DK0672138T3 - Kimære prokoagulante proteiner - Google Patents

Kimære prokoagulante proteiner

Info

Publication number: DK0672138T3
Authority: DK; Denmark
Prior art keywords: factor viii; procoagulant proteins; chimeric; chimeric factor; proteins
Prior art date: 1992-11-13

Application number

DK93923220T

Other languages

English (en)

Inventor

Alnawaz Rehemtulla

Debra Pittman

John M Wozney

Randal J Kaufman

Original Assignee

Inst Genetics Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-13

Filing date

1993-10-01

Publication date

2003-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26819212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0672138(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-10-01 Application filed by Inst Genetics Llc filed Critical Inst Genetics Llc

2003-08-11 Application granted granted Critical

2003-08-11 Publication of DK0672138T3 publication Critical patent/DK0672138T3/da

Links

239000003805 procoagulant Substances 0.000 title abstract 5
102000004169 proteins and genes Human genes 0.000 title abstract 5
108090000623 proteins and genes Proteins 0.000 title abstract 5
108020004414 DNA Proteins 0.000 abstract 1
102000001690 Factor VIII Human genes 0.000 abstract 1
108010054218 Factor VIII Proteins 0.000 abstract 1
208000031220 Hemophilia Diseases 0.000 abstract 1
208000009292 Hemophilia A Diseases 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
229960000301 factor viii Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK93923220T 1992-11-13 1993-10-01 Kimære prokoagulante proteiner DK0672138T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97608692A	1992-11-13	1992-11-13
US08/121,202 US5563045A (en)	1992-11-13	1993-09-14	Chimeric procoagulant proteins
PCT/US1993/009438 WO1994011503A2 (en)	1992-11-13	1993-10-01	Chimeric factor viii

Publications (1)

Publication Number	Publication Date
DK0672138T3 true DK0672138T3 (da)	2003-08-11

Family

ID=26819212

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93923220T DK0672138T3 (da)	1992-11-13	1993-10-01	Kimære prokoagulante proteiner

Country Status (9)

Country	Link
US (1)	US5563045A (da)
EP (2)	EP0672138B1 (da)
AT (1)	ATE239789T1 (da)
AU (1)	AU5298293A (da)
DE (1)	DE69332955T2 (da)
DK (1)	DK0672138T3 (da)
ES (1)	ES2193145T3 (da)
PT (1)	PT672138E (da)
WO (1)	WO1994011503A2 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744446A (en) *	1992-04-07	1998-04-28	Emory University	Hybrid human/animal factor VIII
US6180371B1 (en) *	1996-06-26	2001-01-30	Emory University	Modified factor VIII
US6376463B1 (en)	1992-04-07	2002-04-23	Emory University	Modified factor VIII
US5364771A (en) *	1992-04-07	1994-11-15	Emory University	Hybrid human/porcine factor VIII
US5888974A (en) *	1992-04-07	1999-03-30	Emory University	Hybrid human/animal factor VIII
US5663060A (en) *	1992-04-07	1997-09-02	Emory University	Hybrid human/animal factor VIII
US5859204A (en) *	1992-04-07	1999-01-12	Emory University	Modified factor VIII
SE504074C2 (sv) *	1993-07-05	1996-11-04	Pharmacia Ab	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5910481A (en) *	1995-11-13	1999-06-08	Immuno Ag	Hybrid proteins with modified activity
DE19613620C2 (de) *	1996-04-04	1998-04-16	Steag Micro Tech Gmbh	Verfahren und Vorrichtung zum Trocknen von Substraten
US8183344B2 (en) *	1996-04-24	2012-05-22	University Of Michigan	Inactivation resistant factor VIII
PT1754718E (pt) *	1996-04-24	2011-07-13	Univ Michigan	Factor viii resistente à inactivação
US20040092442A1 (en) *	1996-04-24	2004-05-13	University Of Michigan	Inactivation resistant factor VIII
US6458563B1 (en) *	1996-06-26	2002-10-01	Emory University	Modified factor VIII
US7560107B2 (en)	1996-06-26	2009-07-14	Emory University	Modified factor VIII
US6200560B1 (en) *	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en)	1998-10-20	2001-04-24	Avigen, Inc.	Adeno-associated vectors for expression of factor VIII by target cells
CA2351671A1 (en)	1998-11-24	2000-06-08	Regents Of The University Of Minnesota	Transgenic circulating endothelial cells
US7615622B2 (en)	2001-01-12	2009-11-10	University Of Maryland, Baltimore	Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
US20040143104A1 (en) *	2001-08-08	2004-07-22	Wadsworth Samuel C.	Methods of treating diabetes and other blood sugar disorders
US20040002468A1 (en) *	2001-08-08	2004-01-01	Genzyme Corporation	Methods of treating diabetes and other blood sugar disorders
PT1624891E (pt) *	2003-05-06	2010-01-05	Syntonix Pharmaceuticals Inc	Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
CN1856576B (zh)	2003-09-30	2011-05-04	宾夕法尼亚州立大学托管会	腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20050123997A1 (en) *	2003-10-30	2005-06-09	Lollar John S.	Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en)	2003-10-31	2007-05-01	University Of Maryland, Baltimore	Factor VIII compositions and methods
US20050107318A1 (en) *	2003-11-17	2005-05-19	Samuel Wadsworth	Methods of treating diabetes and other blood sugar disorders
SI1750733T1 (sl) *	2004-05-03	2014-03-31	Emory University	POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
WO2006110689A2 (en)	2005-04-07	2006-10-19	The Trustees Of The University Of Pennsylvania	Method of increasing the function of an aav vector
CA2656558A1 (en) *	2006-06-30	2008-01-10	The Regents Of The University Of Michigan	Method of producing factor viii proteins by recombinant methods
CN102112144A (zh) *	2008-05-16	2011-06-29	拜耳医药保健有限公司	靶向性凝固因子及其使用方法
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
PL3326643T3 (pl)	2009-12-06	2021-10-25	Bioverativ Therapeutics Inc.	Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
US9315825B2 (en)	2010-03-29	2016-04-19	The Trustees Of The University Of Pennsylvania	Pharmacologically induced transgene ablation system
US20130023033A1 (en)	2010-03-29	2013-01-24	The Trustees Of The University Of Pennsylvania	Pharmacologically induced transgene ablation system
EP2591101B1 (en)	2010-07-09	2018-11-07	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
JP5922141B2 (ja)	2010-11-05	2016-05-24	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
DK2675902T3 (da)	2011-02-17	2019-06-03	Univ Pennsylvania	Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
CA2838833A1 (en)	2011-06-10	2012-12-13	Biogen Idec Ma Inc.	Pro-coagulant compounds and methods of use thereof
CN103796670A (zh) *	2011-07-08	2014-05-14	比奥根艾迪克依蒙菲利亚公司	因子viii嵌合和杂合多肽及其使用方法
WO2013016454A1 (en)	2011-07-25	2013-01-31	Biogen Idec Hemophilia Inc.	Assays to monitor bleeding disorders
DK2804623T3 (da)	2012-01-12	2019-11-11	Bioverativ Therapeutics Inc	Kimære faktor viii-polypeptider og anvendelser deraf
EP3970737A1 (en)	2012-01-12	2022-03-23	Bioverativ Therapeutics Inc.	Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
HRP20200007T1 (hr)	2012-07-11	2020-03-20	Bioverativ Therapeutics Inc.	Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
US10001495B2 (en)	2012-07-25	2018-06-19	Bioverativ Therapeutics Inc.	Blood factor monitoring assay and uses thereof
CA2888806A1 (en)	2012-10-18	2014-04-24	Biogen Idec Ma Inc.	Methods of using a fixed dose of a clotting factor
EP3446700A1 (en)	2012-10-30	2019-02-27	Bioverativ Therapeutics Inc.	Methods of using fviii polypeptide
DK2968477T3 (da)	2013-03-15	2020-03-09	Bioverativ Therapeutics Inc	Faktor viii-polypeptidformuleringer
US9719106B2 (en)	2013-04-29	2017-08-01	The Trustees Of The University Of Pennsylvania	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
SG10201710616XA (en)	2013-06-28	2018-02-27	Biogen Ma Inc	Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en)	2013-08-08	2015-02-12	Biogen Idec Ma Inc.	Purification of chimeric fviii molecules
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
US10584147B2 (en)	2013-11-08	2020-03-10	Biovertiv Therapeutics Inc.	Procoagulant fusion compound
US10325687B2 (en)	2013-12-06	2019-06-18	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
AU2015204646B2 (en)	2014-01-10	2020-08-27	Bioverativ Therapeutics Inc.	Factor VIII chimeric proteins and uses thereof
CN115074366A (zh)	2015-04-16	2022-09-20	埃默里大学	用于肝脏中蛋白质表达的重组启动子和载体及其用途
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CN108603198A (zh)	2015-12-16	2018-09-28	新西兰植物与食品研究所	操纵植物发育的组合物和方法
IL319473A (en)	2016-12-02	2025-05-01	Bioverativ Therapeutics Inc	Methods for treating hemophilic arthritis using chimeric blood clotting factors
CN110520149A (zh)	2016-12-02	2019-11-29	比奥维拉迪维治疗股份有限公司	诱导对凝血因子的免疫耐受性的方法
BR112020022164A2 (pt)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	métodos de tratamento de hemofilia a
US12252528B2 (en)	2018-10-23	2025-03-18	The Children's Hospital Of Philadelphia	Compositions and methods for modulating Factor VIII function
JP2023537070A (ja)	2020-08-07	2023-08-30	アミカスセラピューティックスインコーポレイテッド	小胞を標的とするタンパク質及びその使用
WO2024077110A2 (en)	2022-10-05	2024-04-11	Roger Paul Hellens	Uorf::reporter gene fusions to select sequence changes to gene edit into uorfs to regulate ascorbate genes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
WO1985001961A1 (en) *	1983-10-28	1985-05-09	Genetics Institute	Production of factor viii and related products
ATE72838T1 (de)	1985-04-12	1992-03-15	Genetics Inst	Neue prokoagulierungsproteine.
DE3785102T2 (de)	1986-01-03	1993-07-22	Genetics Inst	Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5451521A (en)	1986-05-29	1995-09-19	Genetics Institute, Inc.	Procoagulant proteins
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
CA1331157C (en)	1987-04-06	1994-08-02	Randal J. Kaufman	Method for producing factor viii:c-type proteins
US5004803A (en)	1988-11-14	1991-04-02	Genetics Institute, Inc.	Production of procoagulant proteins
US5364771A (en) *	1992-04-07	1994-11-15	Emory University	Hybrid human/porcine factor VIII

1993
- 1993-09-14 US US08/121,202 patent/US5563045A/en not_active Expired - Lifetime
- 1993-10-01 WO PCT/US1993/009438 patent/WO1994011503A2/en not_active Ceased
- 1993-10-01 DK DK93923220T patent/DK0672138T3/da active
- 1993-10-01 PT PT93923220T patent/PT672138E/pt unknown
- 1993-10-01 AT AT93923220T patent/ATE239789T1/de not_active IP Right Cessation
- 1993-10-01 AU AU52982/93A patent/AU5298293A/en not_active Abandoned
- 1993-10-01 EP EP93923220A patent/EP0672138B1/en not_active Revoked
- 1993-10-01 EP EP02025048A patent/EP1308515A3/en not_active Withdrawn
- 1993-10-01 ES ES93923220T patent/ES2193145T3/es not_active Expired - Lifetime
- 1993-10-01 DE DE69332955T patent/DE69332955T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0672138A1 (en)	1995-09-20
EP1308515A3 (en)	2003-05-28
AU5298293A (en)	1994-06-08
EP1308515A2 (en)	2003-05-07
PT672138E (pt)	2003-09-30
WO1994011503A3 (en)	1994-07-07
ATE239789T1 (de)	2003-05-15
ES2193145T3 (es)	2003-11-01
DE69332955D1 (de)	2003-06-12
WO1994011503A2 (en)	1994-05-26
DE69332955T2 (de)	2004-01-29
US5563045A (en)	1996-10-08
EP0672138B1 (en)	2003-05-07

Publication	Publication Date	Title
DK0672138T3 (da)	2003-08-11	Kimære prokoagulante proteiner
ATE322544T1 (de)	2006-04-15	Hybrider faktor viii aus sequenzen von mensch und schwein
EP0910628A4 (en)	2001-05-02	AGAINST INACTIVATION OF RESISTANT FACTOR VIII
EP0442961A4 (en)	1992-04-08	Hybrid procoagulant proteins
RU95115239A (ru)	1997-03-27	Аналог эритропоэтина
DE69638117D1 (de)	2010-03-04	Varianten des menschlichen Wachstumshormons
DK0409472T3 (da)	1995-01-16	Knoglemorfogenetisk protein
DE69131580D1 (de)	1999-10-07	GDF-1 und UOG1 Proteine
DK0728148T3 (da)	1999-09-27	Forbedrede immunogene sammensætninger mod humant gastrin 17
ATE397062T1 (de)	2008-06-15	Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ATE133556T1 (de)	1996-02-15	Aminosäure-beta-lyase-enzyminhibitoren als deodorantien
AU3793493A (en)	1993-09-13	Therapeutic domains of von willebrand factor
ATE190352T1 (de)	2000-03-15	Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69311183D1 (de)	1997-07-10	Verfahren zur Herstellung von Acryloxy- oder Methacryloxygruppen enthaltenden Organosiliconen
NO177863C (no)	1995-12-06	Fremgangsmåte for fremstilling av rekombinant humant IFN-type I, IFN1, IFN-pseudo-2, -3, og -4, samt ekspresjonsvektorer
IL95863A0 (en)	1991-07-18	Anticoagulant peptides and compositions containing them
DE69328060D1 (de)	2000-04-20	Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
EP0367641A3 (en)	1990-08-29	Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
EP0723016A3 (en)	1997-08-20	Leukocyte activation factor
ATE55411T1 (de)	1990-08-15	Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.